Meet the Team
Kreg Howk, MS, MBA
Founder & Principal Consultant
Kreg has over 25 years of preclinical experience beginning with his time at Charles River Laboratories (1997 to 2007) and then at Covidien/Medtronic (2007 to 2023). As a Senior Scientist at Charles River, Kreg was responsible for the overall technical conduct and integrity of GLP and non-GLP contract preclinical studies as well as the interpretation, analysis, documentation, and reporting of results from studies conducted. Fulfilling the role of Study Director, additional responsibilities included correspondence/collaboration with Sponsors for study development, drafting study outlines and proposals, protocol generation, and oversight of all critical phases of preclinical studies. During his time with Charles River, Kreg worked in the areas of General and Specialized Toxicology, Pharmacology and Metabolic Diseases, Pharmacokinetics, Interventional and Specialized Surgery, and Pharmacology and Experimental Medicine.
Kreg joined Covidien in 2007 as a Principal Research Scientist focusing on preclinical initiatives for Biosurgery which included the development and testing of sealants, adhesion barriers, adhesives, and hemostats. After the acquisition of Covidien by Medtronic in 2015, Kreg served as a Preclinical Research Director providing strategic leadership, technical support, and subject matter expertise to cross functional project teams including R&D, Regulatory Affairs, Quality, Marketing, and Clinical Affairs. Kreg directed the preclinical function and a preclinical team for a global business unit with international collaborations with EMEA, Asia Pacific, and China regions. Areas of focus included soft tissue repair, lung health initiatives, thermal ablation technologies, gastrointestinal diagnostics and treatment, and general surgery applications.
Kreg received his Bachelor of Science degree in Biotechnology from Worcester Polytechnic Institute (Worcester, MA) in 1997. Kreg completed his Master of Science degree in Biotechnology from Worcester State University (Worcester, MA) in 2006. His thesis project investigated the effects of antiplatelet drugs (i.e., aspirin and clopidogrel) on platelet aggregation after oral administration in dogs and pigs as commonly used animal models for vascular intervention studies. Kreg then went on to obtain his Master of Business Administration degree from the University of Massachusetts Isenberg School of Management (Amherst, MA) in 2015.